Semaglutide AdCom meeting conference call

 

Conference call with members from Executive Management on outcome of semaglutide Advisory Committee meeting

On 19 October 2017 at 08.00 am CEST, corresponding to 2.00 am EST, a conference call for investors will be held.

Please use the below link to access the webcast and presentation.

- Conference call link

- Conference call presentation

If you have any questions, you are welcome to contact Novo Nordisk Investor Relations: 

+45 3075 9085              Peter Hugreffe Ankersen
+45 3079 8519              Hanna Ögren
+45 3079 4461              Anders Mikkelsen
+45 3079 3009              Christina Kjær 
+1 609 235 8567           Kasper Veje